Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Neoplasm
100%
Lung Cancer
92%
Malignant Neoplasm
87%
Overall Survival
82%
Osteosarcoma
72%
Ipilimumab
65%
Nivolumab
64%
Diseases
55%
Non Small Cell Lung Cancer
54%
Immune Checkpoint Inhibitor
53%
Cancer
46%
Connective Tissue Cancer
45%
Progression Free Survival
45%
Hazard Ratio
41%
Immunotherapy
40%
Lung Metastasis
36%
Biological Product
36%
Interleukin 11 Receptor
36%
Rheumatoid Arthritis
36%
Inflammatory Arthritis
36%
Hematopoietic Stem Cell Transplantation
36%
Solid Malignant Neoplasm
36%
Surgery
32%
Antirheumatic Agent
32%
Arm
30%
Systemic Therapy
27%
Lung
26%
Adverse Event
25%
Metastatic Carcinoma
22%
Advanced Cancer
22%
Neoadjuvant Therapy
22%
Immunity
21%
Quality Improvement
20%
Adolescence
19%
Sclerosis
19%
Primary Tumor
19%
Proportional Hazards Model
18%
Light Chain
18%
BRCA1
18%
Nerve Sheath Tumor
18%
Prospective Study
18%
Pleura Metastasis
18%
Pazopanib
18%
Preoperative Chemotherapy
18%
Internal Medicine
18%
Early Cancer
18%
Retroperitoneum
18%
Veterans Affairs
18%
Phyllodes Tumor
18%
Talazoparib
18%
Keyphrases
Osteosarcoma
72%
Ipilimumab
64%
Non-small Cell Lung Cancer (NSCLC)
62%
Nivolumab
61%
Overall Survival
52%
Older Adults
45%
Immune Checkpoint Inhibitors
43%
Chemotherapy
41%
Disease-modifying Antirheumatic Drugs (DMARDs)
36%
Lung Metastasis
36%
Interleukin-11 Receptor
36%
Surgical Outcomes
36%
Enhancer of Zeste Homolog 2 (EZH2)
36%
Rheumatoid Arthritis
36%
Signaling Axis
36%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
36%
Therapeutic Strategies
36%
Neoadjuvant
36%
Tumor
36%
Progression-free Survival
33%
High Risk
28%
Clinical Outcomes
27%
Computed Tomography
25%
Clinical Activity
24%
Hazard Ratio
23%
Neoadjuvant Chemotherapy
23%
Retrospective Analysis
22%
Pathologic
22%
Neoadjuvant Therapy
22%
Confidence Interval
21%
Clinical Benefit
21%
Solid Tumors
21%
Clinical Efficacy
20%
Advanced Cancer
19%
Cancer Treatment
19%
Systemic Therapy
19%
Resection
19%
Viable Tumor
19%
Medicine Evaluation
18%
Preoperative Chemotherapy
18%
Resection Specimen
18%
BRCA1, BRCA2
18%
Pazopanib
18%
Retroperitoneum
18%
Phyllodes Tumor
18%
Single Center
18%
Talazoparib
18%
Clinical Safety
18%
Older Patients
18%
Early Cancer
18%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
90%
Malignant Neoplasm
90%
Overall Survival
65%
Diseases
55%
Non Small Cell Lung Cancer
55%
Osteosarcoma
54%
Chemotherapy
47%
Progression Free Survival
38%
Lung Metastasis
36%
Interleukin 11 Receptor
36%
Inflammatory Arthritis
36%
Biological Product
36%
Rheumatoid Arthritis
36%
Solid Malignant Neoplasm
36%
Ipilimumab
32%
Immune Checkpoint Inhibitor
31%
Lung Cancer
30%
Nivolumab
29%
Antirheumatic Agent
27%
Immunotherapy
24%
Advanced Cancer
22%
Selinexor
18%
Pazopanib
18%
Pleura Metastasis
18%
Talazoparib
18%
QT Prolongation
18%
Heat Shock Protein 27
18%
Disease Modifying Antirheumatic Drug
18%
Phosphoglycerate Dehydrogenase
18%
Ovary Cancer
18%
Desmoplastic Small Round Cell Tumor
18%
Sclerosis
18%
Malignant Pleura Effusion
18%
Paclitaxel
18%
Well Differentiated Liposarcoma
18%
Survival Prediction
18%
Effusion
18%
Fragility Fracture
18%
Dedifferentiated Liposarcoma
18%
Isocitrate Dehydrogenase Inhibitor
18%
Cytotoxic T Lymphocyte Antigen 4
18%
CD8 Antigen
16%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor
12%
Toxicity and Intoxication
12%
Phase II Trials
12%
Primary Tumor
11%
Connective Tissue Cancer
9%
Recurrence Free Survival
9%
Metastasis
9%
Monotherapy
9%